|
Q1 FY2027
As of Aug 31, 2026
|
Q4 FY2026
As of May 31, 2026
|
Q3 FY2026
As of Feb 28, 2026
|
Q2 FY2026
As of Nov 30, 2025
|
Q1 FY2026
As of Aug 31, 2025
|
Q4 FY2025
As of May 31, 2025
|
Q3 FY2025
As of Feb 28, 2025
|
Q2 FY2025
As of Nov 30, 2024
|
Q1 FY2025
As of Aug 31, 2024
|
Q4 FY2024
As of May 31, 2024
|
Q3 FY2024
As of Feb 29, 2024
|
Q2 FY2024
As of Nov 30, 2023
|
Q1 FY2024
As of Aug 31, 2023
|
Q4 FY2023
As of May 31, 2023
|
Q3 FY2023
As of Feb 28, 2023
|
Q2 FY2023
As of Nov 30, 2022
|
Q1 FY2023
As of Aug 31, 2022
|
Q4 FY2022
As of May 31, 2022
|
Q3 FY2022
As of Feb 28, 2022
|
Q2 FY2022
As of Nov 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Due to related parties - current | ||||||||||||||||||||
| Notes and advances due to related parties | ||||||||||||||||||||
| Notes and advances payable | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Common stock, $0.001 par value, 500,000,000 shares authorized; 21,141,272 shares issued and outstanding at August 31, 2026 and May 31, 2026 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Obligation to issue shares, equity | ||||||||||||||||||||
| Reserves | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||||||
| Total liabilities and stockholders' deficit | ||||||||||||||||||||
Loading...
